| Stereochemistry | ABSOLUTE |
| Molecular Formula | C24H30ClFN4O4 |
| Molecular Weight | 492.971 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
COC1=CC(N)=C(Cl)C=C1C(=O)NCC2CCN(CC[C@H](OC(N)=O)C3=CC=C(F)C=C3)CC2
InChI
InChIKey=KGMMSPVVHZGPHL-NRFANRHFSA-N
InChI=1S/C24H30ClFN4O4/c1-33-22-13-20(27)19(25)12-18(22)23(31)29-14-15-6-9-30(10-7-15)11-8-21(34-24(28)32)16-2-4-17(26)5-3-16/h2-5,12-13,15,21H,6-11,14,27H2,1H3,(H2,28,32)(H,29,31)/t21-/m0/s1
Relenopride (YKP-10811) is a serotonin 4 (5-HT4) receptor agonist that was developed for regulation of gastric motility. It improved antral contractions and accelerated gastric emptying in dogs and had no adverse effects. Phase II clinical trials have investigated the efficacy and safety of relenopride in patients with (chronic and functional) constipation and irritable bowel syndrome (IBD). Relenopride was reported to accelerate gastrointestinal motility and colonic transit and improve bowel functions in patients with functional constipation, compared with placebo.
Originator
Approval Year
PubMed
ACTIVE MOIETY
SALT/SOLVATE (PARENT)
